170 related articles for article (PubMed ID: 28670108)
1. Lugano 2014 criteria for assessing FDG-PET/CT in lymphoma: an operational approach for clinical trials.
Van Heertum RL; Scarimbolo R; Wolodzko JG; Klencke B; Messmann R; Tunc F; Sokol L; Agarwal R; Strafaci JA; O'Neal M
Drug Des Devel Ther; 2017; 11():1719-1728. PubMed ID: 28670108
[TBL] [Abstract][Full Text] [Related]
2. Intra- and inter-observer agreement in the visual interpretation of interim 18F-FDG PET/CT in malignant lymphoma: influence of clinical information.
Arimoto MK; Nakamoto Y; Higashi T; Ishimori T; Ishibashi M; Togashi K
Acta Radiol; 2018 Oct; 59(10):1218-1224. PubMed ID: 29333861
[TBL] [Abstract][Full Text] [Related]
3.
Sibille L; Seifert R; Avramovic N; Vehren T; Spottiswoode B; Zuehlsdorff S; Schäfers M
Radiology; 2020 Feb; 294(2):445-452. PubMed ID: 31821122
[TBL] [Abstract][Full Text] [Related]
4. Observer variation in interpreting 18F-FDG PET/CT findings for lymphoma staging.
Hofman MS; Smeeton NC; Rankin SC; Nunan T; O'Doherty MJ
J Nucl Med; 2009 Oct; 50(10):1594-7. PubMed ID: 19759113
[TBL] [Abstract][Full Text] [Related]
5. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
[TBL] [Abstract][Full Text] [Related]
6. Renal Masses Detected on FDG PET/CT in Patients With Lymphoma: Imaging Features Differentiating Primary Renal Cell Carcinomas From Renal Lymphomatous Involvement.
Nicolau C; Sala E; Kumar A; Goldman DA; Schoder H; Hricak H; Vargas HA
AJR Am J Roentgenol; 2017 Apr; 208(4):849-853. PubMed ID: 28095016
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic accuracy of FDG PET/CT for clinical evaluation at the end of treatment of HL and NHL: a comparison of the Deauville Criteria (DC) and the International Harmonization Project Criteria (IHPC).
Fallanca F; Alongi P; Incerti E; Gianolli L; Picchio M; Kayani I; Bomanji J
Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1837-48. PubMed ID: 27154522
[TBL] [Abstract][Full Text] [Related]
8. The (68)Ge phantom-based FDG-PET site qualification program for clinical trials adopted by FIL (Italian Foundation on Lymphoma).
Chauvie S; Bergesio F; Fioroni F; Brambilla M; Biggi A; Versari A; Guerra L; Storto G; Musto P; Luminari S; Cabras MG; Balzarotti M; Rigacci L; Martelli M; Vitolo U; Federico M; Gallamini A
Phys Med; 2016 May; 32(5):651-6. PubMed ID: 27133138
[TBL] [Abstract][Full Text] [Related]
9. The role of 18F-FDG PET/CT in staging and restaging primary bone lymphoma.
Liu Y
Nucl Med Commun; 2017 Apr; 38(4):319-324. PubMed ID: 28225435
[TBL] [Abstract][Full Text] [Related]
10. Whole-body MRI, FDG-PET/CT, and bone marrow biopsy, for the assessment of bone marrow involvement in patients with newly diagnosed lymphoma.
Albano D; Patti C; Lagalla R; Midiri M; Galia M
J Magn Reson Imaging; 2017 Apr; 45(4):1082-1089. PubMed ID: 27603267
[TBL] [Abstract][Full Text] [Related]
11. Utility of Bone Marrow Biopsy and Aspirate for Staging of Diffuse Large B Cell Lymphoma in the Era of Positron Emission Tomography With 2-Deoxy-2-[Fluorine-18]fluoro-deoxyglucose Integrated With Computed Tomography.
Vishnu P; Wingerson A; Lee M; Mandelson MT; Aboulafia DM
Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):631-636. PubMed ID: 28684378
[TBL] [Abstract][Full Text] [Related]
12. Prognostic role of baseline
Albano D; Bosio G; Camoni L; Farina M; Re A; Tucci A; Giubbini R; Bertagna F
Hematol Oncol; 2019 Feb; 37(1):39-46. PubMed ID: 30299563
[TBL] [Abstract][Full Text] [Related]
13. Positron emission tomography with 18-fluorodeoxyglucose in the staging and follow-up of lymphoma in the chest.
Bangerter M; Kotzerke J; Griesshammer M; Elsner K; Reske SN; Bergmann L
Acta Oncol; 1999; 38(6):799-804. PubMed ID: 10522771
[TBL] [Abstract][Full Text] [Related]
14.
Tamayo P; Martín A; Díaz L; Cabrero M; García R; García-Talavera P; Caballero D
Rev Esp Med Nucl Imagen Mol; 2017; 36(5):312-321. PubMed ID: 28483374
[TBL] [Abstract][Full Text] [Related]
15. Early evaluation of tumor response to
Kitajima K; Okada M; Kashiwagi T; Yoshihara K; Tokugawa T; Sawada A; Yoshihara S; Fujimori Y; Yamakado K
Eur Radiol; 2019 Jul; 29(7):3935-3944. PubMed ID: 30899979
[TBL] [Abstract][Full Text] [Related]
16. Automated quantification of reference levels in liver and mediastinal blood pool for the Deauville therapy response classification using FDG-PET/CT in Hodgkin and non-Hodgkin lymphomas.
Sadik M; Lind E; Polymeri E; Enqvist O; Ulén J; Trägårdh E
Clin Physiol Funct Imaging; 2019 Jan; 39(1):78-84. PubMed ID: 30284376
[TBL] [Abstract][Full Text] [Related]
17. Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe).
Nanni C; Zamagni E; Versari A; Chauvie S; Bianchi A; Rensi M; Bellò M; Rambaldi I; Gallamini A; Patriarca F; Gay F; Gamberi B; Cavo M; Fanti S
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):414-21. PubMed ID: 26475305
[TBL] [Abstract][Full Text] [Related]
18. Correlations between maximum standardized uptake value measured via
Li H; Wang X; Zhang L; Yi X; Qiao Y; Jin Q
J Cancer Res Ther; 2019; 15(7):1581-1588. PubMed ID: 31939441
[TBL] [Abstract][Full Text] [Related]
19. Comparison of
Kaste SC; Snyder SE; Metzger ML; Sandlund JT; Howard SC; Krasin M; Shulkin BL
J Nucl Med; 2017 Mar; 58(3):419-424. PubMed ID: 27609791
[TBL] [Abstract][Full Text] [Related]
20. Post-treatment positron emission tomography-computed tomography is highly predictive of outcome in Plasmablastic lymphoma.
Al Tabaa Y; Tchernonog E; Faurie P; Cottereau AS; Monjanel H; Bonnet A; Le Gouill S; Gyan E; Ghesquieres H; Mariano-Goulart D; Cartron G
Eur J Nucl Med Mol Imaging; 2018 Sep; 45(10):1705-1709. PubMed ID: 29679112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
